KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Leases (2016 - 2025)

Vertex Pharmaceuticals has reported Leases over the past 16 years, most recently at $81.5 million for Q4 2025.

  • Quarterly results put Leases at $81.5 million for Q4 2025, up 40.76% from a year ago — trailing twelve months through Dec 2025 was $81.5 million (up 40.76% YoY), and the annual figure for FY2025 was $81.5 million, up 40.76%.
  • Leases for Q4 2025 was $81.5 million at Vertex Pharmaceuticals, down from $1.6 billion in the prior quarter.
  • Over the last five years, Leases for VRTX hit a ceiling of $1.6 billion in Q3 2025 and a floor of $57.9 million in Q4 2024.
  • Median Leases over the past 5 years was $323.3 million (2021), compared with a mean of $528.2 million.
  • Peak annual rise in Leases hit 349.63% in 2024, while the deepest fall reached 78.78% in 2024.
  • Vertex Pharmaceuticals' Leases stood at $400.1 million in 2021, then fell by 21.14% to $315.5 million in 2022, then decreased by 13.53% to $272.8 million in 2023, then crashed by 78.78% to $57.9 million in 2024, then surged by 40.76% to $81.5 million in 2025.
  • The last three reported values for Leases were $81.5 million (Q4 2025), $1.6 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.